Related Experiment Videos
Antidotes to haemorrhage: recombinant factor VIIa
1Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3800 Reservoir Road, NW, Washington, DC 20007, USA. kesslerc@gunet.georgetown.edu
Best Practice & Research. Clinical Haematology
|June 3, 2004
Summary
Recombinant Factor VIIa (rFVIIa) is used widely for bleeding but lacks strong clinical trial evidence. More research is needed to confirm its safety and effectiveness for various bleeding conditions.
Area of Science:
- Hematology
- Pharmacology
Background:
- Recombinant Factor VIIa (rFVIIa) was developed for hemophilia bleeding.
- Its use expanded to other bleeding conditions due to perceived efficacy.
- Current application as a 'universal pancoagulant' lacks robust clinical trial support.
Purpose of the Study:
- To review the existing evidence for rFVIIa in managing bleeding complications.
- To highlight the limitations of current empirical dosing strategies.
- To emphasize the need for evidence-based data to define rFVIIa's role.
Main Methods:
- Review of anecdotal experience with rFVIIa.
- Analysis of limited controlled clinical trials.
- Discussion of physiological understanding of rFVIIa.
Main Results:
- rFVIIa use has expanded beyond its original indication in hemophilia.
- Empirical dosing strategies have not been optimized for effective bleeding control.
- There is a significant lack of well-designed, adequately powered clinical trials.
Conclusions:
- The widespread use of rFVIIa as a 'universal pancoagulant' is not supported by sufficient evidence.
- Evidence-based data are crucial to establish the cost-benefit and risk-benefit profiles of rFVIIa.
- Further clinical trials are necessary to validate rFVIIa as a standard treatment for bleeding.